Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CRISPR Therapeutics AGCRSP · Entity 3852 | General Counsel and Secretary | October 06, 2026 | October 08, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CRISPR Therapeutics AG
Report date October 06, 2026 · Filed October 08, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common SharesSEC Table I · non-derivative | Direct | 94,784 |
Ending reported balance
After 2026-10-06 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-10-06 · Exercise / conversion · Acquired 1,990 · Balance 96,774 Row 2 · 2026-10-06 · Sale · Disposed 1,990 · Balance 94,784 F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 6, 2026. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.00 to $60.08, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.62 · Expires 2027-05-31 | Direct | 81,242 |
Reported balance
After 2026-10-06 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-10-06 · Exercise / conversion · Disposed 1,990 · Balance 81,242 F3: This option was granted on May 31, 2017 with respect to 123,000 Common Shares of which 25% shall vest on May 31, 2018 and the remaining 75% shall vest monthly thereafter for 36 months. |
Filing footnotes · ownership attribution and instrument terms
F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 6, 2026.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.00 to $60.08, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F3: This option was granted on May 31, 2017 with respect to 123,000 Common Shares of which 25% shall vest on May 31, 2018 and the remaining 75% shall vest monthly thereafter for 36 months.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 11, 2024 Filed Mar 12, 2024 21:45 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionRestricted Stock Units · Derivative | 2,250 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-030190 · ownership.xml · derivative · entry 6 KASINGER JAMES R. · CIK 0001708172 · General Counsel and Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,250 Underlying: Common Shares · 2,250 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. F1 · price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. F4 · derivative.exercise_date: This restricted stock unit award was granted on March 11, 2021 with respect to 9,000 Common Shares, with (i) one quarter of the shares vesting on March 11, 2022, (ii) one quarter of the shares vesting on March 11, 2023, (iii) one quarter of the shares vesting on March 11, 2024, and (iv) one quarter of the shares vesting on March 11, 2025. F4 · derivative.expiration_date: This restricted stock unit award was granted on March 11, 2021 with respect to 9,000 Common Shares, with (i) one quarter of the shares vesting on March 11, 2022, (ii) one quarter of the shares vesting on March 11, 2023, (iii) one quarter of the shares vesting on March 11, 2024, and (iv) one quarter of the shares vesting on March 11, 2025. Read SEC document |
| March 11, 2024 Filed Mar 12, 2024 21:45 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionCommon Shares | 2,250 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-030190 · ownership.xml · nonDerivative · entry 3 KASINGER JAMES R. · CIK 0001708172 · General Counsel and Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 62,320 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. Read SEC document |
| March 11, 2024 Filed Mar 12, 2024 21:45 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | SaleCommon Shares | 2,801 | $78.26 | $219,206.26 |
DisclosureSEC source: 0000950170-24-030190 · ownership.xml · nonDerivative · entry 2 KASINGER JAMES R. · CIK 0001708172 · General Counsel and Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,070 F2 · shares: Amount reported represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of these restricted stock units. This sale is mandated by the Company's RSU Settlement Policy to fund the tax withholding obligation and does not represent a discretionary trade by the reporting person. Read SEC document |
| March 10, 2024 Filed Mar 12, 2024 21:45 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionRestricted Stock Units · Derivative | 5,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-030190 · ownership.xml · derivative · entry 5 KASINGER JAMES R. · CIK 0001708172 · General Counsel and Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,500 Underlying: Common Shares · 5,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. F1 · price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. F3 · derivative.exercise_date: This restricted stock unit award was granted on March 10, 2023 with respect to 22,000 Common Shares, with (i) one quarter of the shares vesting on March 10, 2024, (ii) one quarter of the shares vesting on March 10, 2025, (iii) one quarter of the shares vesting on March 10, 2026, and (iv) one quarter of the shares vesting on March 10, 2027. F3 · derivative.expiration_date: This restricted stock unit award was granted on March 10, 2023 with respect to 22,000 Common Shares, with (i) one quarter of the shares vesting on March 10, 2024, (ii) one quarter of the shares vesting on March 10, 2025, (iii) one quarter of the shares vesting on March 10, 2026, and (iv) one quarter of the shares vesting on March 10, 2027. Read SEC document |
| March 10, 2024 Filed Mar 12, 2024 21:45 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionCommon Shares | 5,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-030190 · ownership.xml · nonDerivative · entry 1 KASINGER JAMES R. · CIK 0001708172 · General Counsel and Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 62,871 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. Read SEC document |
| February 20, 2024 Filed Feb 21, 2024 22:45 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | SaleCommon Shares | 1,913 | $79.67 | $152,408.71 |
DisclosureSEC source: 0000950170-24-018175 · ownership.xml · nonDerivative · entry 2 KASINGER JAMES R. · CIK 0001708172 · General Counsel and Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 57,371 F3 · shares: Amount reported represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of these restricted stock units. This sale is mandated by the Company's RSU Settlement Policy to fund the tax withholding obligation and does not represent a discretionary trade by the reporting person. Read SEC document |
| February 18, 2024 Filed Feb 21, 2024 22:45 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionRestricted Stock Units · Derivative | 3,825 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-018175 · ownership.xml · derivative · entry 3 KASINGER JAMES R. · CIK 0001708172 · General Counsel and Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,650 Underlying: Common Shares · 3,825 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. F1 · price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. F4 · derivative.exercise_date: This restricted stock unit award was granted on February 18, 2022 with respect to 15,300 Common Shares, with (i) one quarter of the shares vesting on February 18, 2023, (ii) one quarter of the shares vesting on February 18, 2024, (iii) one quarter of the shares vesting on February 18, 2025, and (iv) one quarter of the shares vesting on February 18, 2026. F4 · derivative.expiration_date: This restricted stock unit award was granted on February 18, 2022 with respect to 15,300 Common Shares, with (i) one quarter of the shares vesting on February 18, 2023, (ii) one quarter of the shares vesting on February 18, 2024, (iii) one quarter of the shares vesting on February 18, 2025, and (iv) one quarter of the shares vesting on February 18, 2026. Read SEC document |
| February 18, 2024 Filed Feb 21, 2024 22:45 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionCommon Shares | 3,825 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-018175 · ownership.xml · nonDerivative · entry 1 KASINGER JAMES R. · CIK 0001708172 · General Counsel and Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 59,284 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. F2 · balance_after: Includes 615 shares acquired under the CRISPR Therapeutics AG 2016 Employee Stock Purchase Plan. Read SEC document |
| October 13, 2023 Filed Oct 17, 2023 21:48 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | GrantRestricted Stock Units · Derivative | 6,340 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-23-053817 · ownership.xml · derivative · entry 2 KASINGER JAMES R. · CIK 0001708172 · General Counsel and Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,340 Underlying: Common Shares · 6,340 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. F3 · derivative.exercise_date: This restricted stock unit award was granted on October 13, 2023 with respect to 6,340 Common Shares, with (i) one third of the shares vesting on October 13, 2024, (ii) one third of the shares vesting on October 13, 2025, and (iii) one third of the shares vesting on October 13, 2026. F3 · derivative.expiration_date: This restricted stock unit award was granted on October 13, 2023 with respect to 6,340 Common Shares, with (i) one third of the shares vesting on October 13, 2024, (ii) one third of the shares vesting on October 13, 2025, and (iii) one third of the shares vesting on October 13, 2026. Read SEC document |
| October 13, 2023 Filed Oct 17, 2023 21:48 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | GrantStock Option (Right to Buy) · Derivative | 16,667 | $0.00 Strike: $44.31 | $0.00 |
DisclosureSEC source: 0000950170-23-053817 · ownership.xml · derivative · entry 1 KASINGER JAMES R. · CIK 0001708172 · General Counsel and Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,667 Underlying: Common Shares · 16,667 shares Expires 2033-10-13 F1 · derivative.exercise_date: This option was granted on October 13, 2023 with respect to 16,667 Common Shares. 100% of the shares will vest in 48 equal monthly installments, with the first vesting date of November 13, 2023. Read SEC document |
| March 13, 2023 Filed Mar 14, 2023 21:45 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Tax withholdingCommon Shares | 1,022 | $43.22 | $44,170.84 |
DisclosureSEC source: 0001209191-23-018564 · doc4.xml · nonDerivative · entry 4 KASINGER JAMES R. · CIK 0001708172 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,844 F2 · shares: Amount reported represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of these restricted stock units. This sale is mandated by the Company's RSU Settlement Policy to fund the tax withholding obligation and does not represent a discretionary trade by the reporting person. Read SEC document |
| March 13, 2023 Filed Mar 14, 2023 21:45 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Tax withholdingCommon Shares | 1,283 | $43.22 | $55,451.26 |
DisclosureSEC source: 0001209191-23-018564 · doc4.xml · nonDerivative · entry 2 KASINGER JAMES R. · CIK 0001708172 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,616 F2 · shares: Amount reported represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of these restricted stock units. This sale is mandated by the Company's RSU Settlement Policy to fund the tax withholding obligation and does not represent a discretionary trade by the reporting person. Read SEC document |
| March 11, 2023 Filed Mar 14, 2023 21:45 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionRestricted Stock Units · Derivative | 2,250 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-018564 · doc4.xml · derivative · entry 8 KASINGER JAMES R. · CIK 0001708172 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,500 Underlying: Common Shares · 2,250 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. F1 · price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. F6 · derivative.exercise_date: This restricted stock unit award was granted on March 11, 2021 with respect to 9,000 Common Shares, with (i) one quarter of the shares vesting on March 11, 2022, (ii) one quarter of the shares vesting on March 11, 2023, (iii) one quarter of the shares vesting on March 11, 2024, and (iv) one quarter of the shares vesting on March 11, 2025. F6 · derivative.expiration_date: This restricted stock unit award was granted on March 11, 2021 with respect to 9,000 Common Shares, with (i) one quarter of the shares vesting on March 11, 2022, (ii) one quarter of the shares vesting on March 11, 2023, (iii) one quarter of the shares vesting on March 11, 2024, and (iv) one quarter of the shares vesting on March 11, 2025. Read SEC document |
| March 11, 2023 Filed Mar 14, 2023 21:45 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionCommon Shares | 2,250 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-018564 · doc4.xml · nonDerivative · entry 3 KASINGER JAMES R. · CIK 0001708172 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,866 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. Read SEC document |
| March 10, 2023 Filed Mar 14, 2023 21:45 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | GrantRestricted Stock Units · Derivative | 22,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-018564 · doc4.xml · derivative · entry 7 KASINGER JAMES R. · CIK 0001708172 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,000 Underlying: Common Shares · 22,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. F5 · derivative.exercise_date: This restricted stock unit award was granted on March 10, 2023 with respect to 22,000 Common Shares, with (i) one quarter of the shares vesting on March 10, 2024, (ii) one quarter of the shares vesting on March 10, 2025, (iii) one quarter of the shares vesting on March 10, 2026, and (iv) one quarter of the shares vesting on March 10, 2027. F5 · derivative.expiration_date: This restricted stock unit award was granted on March 10, 2023 with respect to 22,000 Common Shares, with (i) one quarter of the shares vesting on March 10, 2024, (ii) one quarter of the shares vesting on March 10, 2025, (iii) one quarter of the shares vesting on March 10, 2026, and (iv) one quarter of the shares vesting on March 10, 2027. Read SEC document |
| March 10, 2023 Filed Mar 14, 2023 21:45 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | GrantStock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $43.22 | $0.00 |
DisclosureSEC source: 0001209191-23-018564 · doc4.xml · derivative · entry 6 KASINGER JAMES R. · CIK 0001708172 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Shares · 40,000 shares Expires 2033-03-10 F4 · derivative.exercise_date: This option was granted on March 10, 2023 with respect to 40,000 Common Shares. 100% of the shares will vest in 48 equal monthly installments, with the first vesting date of April 10, 2023. Read SEC document |
| March 10, 2023 Filed Mar 14, 2023 21:45 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionRestricted Stock Units · Derivative | 2,833 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-018564 · doc4.xml · derivative · entry 5 KASINGER JAMES R. · CIK 0001708172 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 2,833 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. F1 · price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. F3 · derivative.exercise_date: This restricted stock unit award was granted on March 10, 2020 with respect to 8,500 Common Shares, with (i) one third of the shares vesting on March 10, 2021, (ii) one third of the shares vesting on March 10, 2022, and (iii) one third of the shares vesting on March 10, 2023. F3 · derivative.expiration_date: This restricted stock unit award was granted on March 10, 2020 with respect to 8,500 Common Shares, with (i) one third of the shares vesting on March 10, 2021, (ii) one third of the shares vesting on March 10, 2022, and (iii) one third of the shares vesting on March 10, 2023. Read SEC document |
| March 10, 2023 Filed Mar 14, 2023 21:45 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionCommon Shares | 2,833 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-018564 · doc4.xml · nonDerivative · entry 1 KASINGER JAMES R. · CIK 0001708172 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,899 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. Read SEC document |
| February 21, 2023 Filed Feb 22, 2023 22:35 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Tax withholdingCommon Shares | 1,950 | $48.26 | $94,107.00 |
DisclosureSEC source: 0001209191-23-011777 · doc4.xml · nonDerivative · entry 2 KASINGER JAMES R. · CIK 0001708172 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,066 F2 · shares: Amount reported represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of these restricted stock units. This sale is mandated by the Company's RSU Settlement Policy to fund the tax withholding obligation and does not represent a discretionary trade by the reporting person. Read SEC document |
| February 18, 2023 Filed Feb 22, 2023 22:35 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionRestricted Stock Units · Derivative | 3,825 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-011777 · doc4.xml · derivative · entry 3 KASINGER JAMES R. · CIK 0001708172 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,475 Underlying: Common Shares · 3,825 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. F1 · price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. F3 · derivative.exercise_date: This restricted stock unit award was granted on February 18, 2022 with respect to 15,300 Common Shares, with (i) one quarter of the shares vesting on February 18, 2023, (ii) one quarter of the shares vesting on February 18, 2024, (iii) one quarter of the shares vesting on February 18, 2025, and (iv) one quarter of the shares vesting on February 18, 2026. F3 · derivative.expiration_date: This restricted stock unit award was granted on February 18, 2022 with respect to 15,300 Common Shares, with (i) one quarter of the shares vesting on February 18, 2023, (ii) one quarter of the shares vesting on February 18, 2024, (iii) one quarter of the shares vesting on February 18, 2025, and (iv) one quarter of the shares vesting on February 18, 2026. Read SEC document |
| February 18, 2023 Filed Feb 22, 2023 22:35 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionCommon Shares | 3,825 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-011777 · doc4.xml · nonDerivative · entry 1 KASINGER JAMES R. · CIK 0001708172 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,016 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. Read SEC document |
| December 05, 2022 Filed Dec 6, 2022 22:47 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Tax withholdingCommon Shares | 3,234 | $52.26 | $169,008.84 |
DisclosureSEC source: 0001209191-22-060090 · doc4.xml · nonDerivative · entry 2 KASINGER JAMES R. · CIK 0001708172 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,191 F4 · kind: On December 3, 2019, the reporting person was granted 20,000 restricted stock units. On December 3, 2022, 6,667 restricted stock units vested. Amount reported represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of these restricted stock units. This sale is mandated by the Company's RSU Settlement Policy to fund the tax withholding obligation and does not represent a discretionary trade by the reporting person. Read SEC document |
| December 03, 2022 Filed Dec 6, 2022 22:47 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionRestricted Stock Units · Derivative | 6,667 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-060090 · doc4.xml · derivative · entry 3 KASINGER JAMES R. · CIK 0001708172 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 6,667 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. F2 · price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. F1 · derivative.exercise_date: The restricted stock units shall vest as follows: two-thirds of the grant shall vest on December 3, 2021 and the remaining one-third shall vest on December 3, 2022. F1 · derivative.expiration_date: The restricted stock units shall vest as follows: two-thirds of the grant shall vest on December 3, 2021 and the remaining one-third shall vest on December 3, 2022. Read SEC document |
| December 03, 2022 Filed Dec 6, 2022 22:47 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionCommon Shares | 6,667 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-060090 · doc4.xml · nonDerivative · entry 1 KASINGER JAMES R. · CIK 0001708172 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,425 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The restricted stock units shall vest as follows: two-thirds of the grant shall vest on December 3, 2021 and the remaining one-third shall vest on December 3, 2022. F2 · price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. F3 · balance_after: Includes 329 shares acquired under the CRISPR Therapeutics AG 2016 Employee Stock Purchase Plan. Read SEC document |
| October 07, 2022 Filed Oct 12, 2022 21:40 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | GrantStock Option (Right to Buy) · Derivative | 14,000 | $0.00 Strike: $61.65 | $0.00 |
DisclosureSEC source: 0001209191-22-053494 · doc4.xml · derivative · entry 1 KASINGER JAMES R. · CIK 0001708172 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,000 Underlying: Common Shares · 14,000 shares Expires 2032-10-07 F1 · derivative.exercise_date: This option was granted on October 7, 2022 with respect to 14,000 Common Shares. 100% of the shares will vest in 48 equal monthly installments, with the first vesting date of November 7, 2022. Read SEC document |
| August 16, 2022 Filed Aug 18, 2022 21:33 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | GrantRestricted Stock Units · Derivative | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-046707 · doc4.xml · derivative · entry 1 KASINGER JAMES R. · CIK 0001708172 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Shares · 20,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. F2 · derivative.exercise_date: The restricted stock units shall vest in full on February 16, 2025, subject to continued service to the Company or any of its subsidiaries. F2 · derivative.expiration_date: The restricted stock units shall vest in full on February 16, 2025, subject to continued service to the Company or any of its subsidiaries. Read SEC document |
| March 14, 2022 Filed Mar 14, 2022 22:01 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Tax withholdingCommon Shares | 1,039 | $61.08 | $63,462.12 |
DisclosureSEC source: 0001209191-22-018609 · doc4.xml · nonDerivative · entry 4 KASINGER JAMES R. · CIK 0001708172 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,429 F3 · shares: Amount reported represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of these restricted stock units. This sale is mandated by the Company's RSU Settlement Policy to fund the tax withholding obligation and does not represent a discretionary trade by the reporting person. Read SEC document |
| March 11, 2022 Filed Mar 14, 2022 22:01 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionRestricted Stock Units · Derivative | 2,250 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-018609 · doc4.xml · derivative · entry 6 KASINGER JAMES R. · CIK 0001708172 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,750 Underlying: Common Shares · 2,250 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. F1 · price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. F5 · derivative.exercise_date: This restricted stock unit award was granted on March 11, 2021 with respect to 9,000 Common Shares, with (i) one quarter of the shares vesting on March 11, 2022, (ii) one quarter of the shares vesting on March 11, 2023, (iii) one quarter of the shares vesting on March 11, 2024, and (iv) one quarter of the shares vesting on March 11, 2025. F5 · derivative.expiration_date: This restricted stock unit award was granted on March 11, 2021 with respect to 9,000 Common Shares, with (i) one quarter of the shares vesting on March 11, 2022, (ii) one quarter of the shares vesting on March 11, 2023, (iii) one quarter of the shares vesting on March 11, 2024, and (iv) one quarter of the shares vesting on March 11, 2025. Read SEC document |
| March 11, 2022 Filed Mar 14, 2022 22:01 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionCommon Shares | 2,250 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-018609 · doc4.xml · nonDerivative · entry 3 KASINGER JAMES R. · CIK 0001708172 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,468 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. Read SEC document |
| March 11, 2022 Filed Mar 14, 2022 22:01 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Tax withholdingCommon Shares | 1,321 | $62.56 | $82,641.76 |
DisclosureSEC source: 0001209191-22-018609 · doc4.xml · nonDerivative · entry 2 KASINGER JAMES R. · CIK 0001708172 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,218 F3 · shares: Amount reported represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of these restricted stock units. This sale is mandated by the Company's RSU Settlement Policy to fund the tax withholding obligation and does not represent a discretionary trade by the reporting person. Read SEC document |
| March 10, 2022 Filed Mar 14, 2022 22:01 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionRestricted Stock Units · Derivative | 2,834 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-018609 · doc4.xml · derivative · entry 5 KASINGER JAMES R. · CIK 0001708172 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,833 Underlying: Common Shares · 2,834 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. F1 · price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. F4 · derivative.exercise_date: This restricted stock unit award was granted on March 10, 2020 with respect to 8,500 Common Shares, with (i) one third of the shares vesting on March 10, 2021, (ii) one third of the shares vesting on March 10, 2022, and (iii) one third of the shares vesting on March 10, 2023. F4 · derivative.expiration_date: This restricted stock unit award was granted on March 10, 2020 with respect to 8,500 Common Shares, with (i) one third of the shares vesting on March 10, 2021, (ii) one third of the shares vesting on March 10, 2022, and (iii) one third of the shares vesting on March 10, 2023. Read SEC document |
| March 10, 2022 Filed Mar 14, 2022 22:01 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionCommon Shares | 2,834 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-018609 · doc4.xml · nonDerivative · entry 1 KASINGER JAMES R. · CIK 0001708172 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,539 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. F2 · balance_after: Includes 163 shares acquired under the CRISPR Therapeutics AG 2016 Employee Stock Purchase Plan. Read SEC document |
| February 18, 2022 Filed Feb 22, 2022 22:40 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | GrantRestricted Stock Units · Derivative | 15,300 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-011836 · doc4.xml · derivative · entry 2 KASINGER JAMES R. · CIK 0001708172 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,300 Underlying: Common Shares · 15,300 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. F3 · derivative.exercise_date: This restricted stock unit award was granted on February 18, 2022 with respect to 15,300 Common Shares, with (i) one quarter of the shares vesting on February 18, 2023, (ii) one quarter of the shares vesting on February 18, 2024, (iii) one quarter of the shares vesting on February 18, 2025, and (iv) one quarter of the shares vesting on February 18, 2026. F3 · derivative.expiration_date: This restricted stock unit award was granted on February 18, 2022 with respect to 15,300 Common Shares, with (i) one quarter of the shares vesting on February 18, 2023, (ii) one quarter of the shares vesting on February 18, 2024, (iii) one quarter of the shares vesting on February 18, 2025, and (iv) one quarter of the shares vesting on February 18, 2026. Read SEC document |
| February 18, 2022 Filed Feb 22, 2022 22:40 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | GrantStock Option (Right to Buy) · Derivative | 34,200 | $0.00 Strike: $58.29 | $0.00 |
DisclosureSEC source: 0001209191-22-011836 · doc4.xml · derivative · entry 1 KASINGER JAMES R. · CIK 0001708172 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,200 Underlying: Common Shares · 34,200 shares Expires 2032-02-18 F1 · derivative.exercise_date: This option was granted on February 18, 2022 with respect to 34,200 Common Shares. 100% of the shares will vest in 48 equal monthly installments, with the first vesting date of March 18, 2022. Read SEC document |
| December 06, 2021 Filed Dec 8, 2021 01:00 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Tax withholdingCommon Shares | 6,303 | $69.17 | $435,978.51 |
DisclosureSEC source: 0001209191-21-068453 · doc4.xml · nonDerivative · entry 2 KASINGER JAMES R. · CIK 0001708172 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,542 F3 · kind: On December 3, 2019, the reporting person was granted 20,000 restricted stock units. On December 3, 2021, 13,333 restricted stock units vested. Amount reported represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of these restricted stock units. This sale is mandated by the Company's RSU Settlement Policy to fund the tax withholding obligation and does not represent a discretionary trade by the reporting person. Read SEC document |
| December 03, 2021 Filed Dec 8, 2021 01:00 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionRestricted Stock Units · Derivative | 13,333 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-068453 · doc4.xml · derivative · entry 3 KASINGER JAMES R. · CIK 0001708172 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,667 Underlying: Common Shares · 13,333 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. F2 · price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. F1 · derivative.exercise_date: The restricted stock units shall vest as follows: two-thirds of the grant shall vest on December 3, 2021 and the remaining one-third shall vest on December 3, 2022. F1 · derivative.expiration_date: The restricted stock units shall vest as follows: two-thirds of the grant shall vest on December 3, 2021 and the remaining one-third shall vest on December 3, 2022. Read SEC document |
| December 03, 2021 Filed Dec 8, 2021 01:00 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionCommon Shares | 13,333 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-068453 · doc4.xml · nonDerivative · entry 1 KASINGER JAMES R. · CIK 0001708172 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,845 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The restricted stock units shall vest as follows: two-thirds of the grant shall vest on December 3, 2021 and the remaining one-third shall vest on December 3, 2022. F2 · price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. Read SEC document |
| December 02, 2021 Filed Dec 4, 2021 01:00 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionStock Option (Right to Buy) · Derivative | 7,342 | $0.00 Strike: $13.62 | $0.00 |
DisclosureSEC source: 0001209191-21-068014 · doc4.xml · derivative · entry 2 KASINGER JAMES R. · CIK 0001708172 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,632 Underlying: Common Shares · 7,342 shares Expires 2027-05-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This option was granted on May 31, 2017 with respect to 123,000 Common Shares of which 25% vested on May 31, 2018 and the remaining 75% shall vest monthly thereafter for 36 months. Read SEC document |
| December 02, 2021 Filed Dec 4, 2021 01:00 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionCommon Shares | 7,342 | $13.62 | $99,998.04 |
DisclosureSEC source: 0001209191-21-068014 · doc4.xml · nonDerivative · entry 1 KASINGER JAMES R. · CIK 0001708172 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,512 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 15, 2021 Filed Oct 19, 2021 00:00 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | GrantStock Option (Right to Buy) · Derivative | 10,800 | $0.00 Strike: $97.00 | $0.00 |
DisclosureSEC source: 0001209191-21-060778 · doc4.xml · derivative · entry 1 KASINGER JAMES R. · CIK 0001708172 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,800 Underlying: Common Shares · 10,800 shares Expires 2031-10-15 F1 · derivative.exercise_date: This option was granted on October 15, 2021 with respect to 10,800 Common Shares. 100% of the shares will vest in 48 equal monthly installments, with the first vesting date of November 15, 2021. Read SEC document |
| September 13, 2021 Filed Sep 15, 2021 01:45 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Tax withholdingCommon Shares | 4,741 | $117.86 | $558,774.26 |
DisclosureSEC source: 0001209191-21-056093 · doc4.xml · nonDerivative · entry 2 KASINGER JAMES R. · CIK 0001708172 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,170 F3 · kind: Amount reported represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of these restricted stock units. This sale is mandated by the Company's RSU Settlement Policy to fund the tax withholding obligation and does not represent a discretionary trade by the reporting person. Read SEC document |
| September 10, 2021 Filed Sep 15, 2021 01:45 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Disposition to issuerRestricted Stock Units · Derivative | 10,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-056093 · doc4.xml · derivative · entry 3 KASINGER JAMES R. · CIK 0001708172 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 10,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. F2 · price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. F1 · derivative.exercise_date: The restricted stock unit award was granted on September 10, 2019 with respect to 10,000 Common Shares, with all shares vesting on September 10, 2021. F1 · derivative.expiration_date: The restricted stock unit award was granted on September 10, 2019 with respect to 10,000 Common Shares, with all shares vesting on September 10, 2021. Read SEC document |
| September 10, 2021 Filed Sep 15, 2021 01:45 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionCommon Shares | 10,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-056093 · doc4.xml · nonDerivative · entry 1 KASINGER JAMES R. · CIK 0001708172 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,911 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The restricted stock unit award was granted on September 10, 2019 with respect to 10,000 Common Shares, with all shares vesting on September 10, 2021. F2 · price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. Read SEC document |
| March 11, 2021 Filed Mar 12, 2021 22:43 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | GrantRestricted Stock Units · Derivative | 9,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-020253 · doc4.xml · derivative · entry 4 KASINGER JAMES R. · CIK 0001708172 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,000 Underlying: Common Shares · 9,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. F5 · derivative.exercise_date: This restricted stock unit award was granted on March 11, 2021 with respect to 9,000 Common Shares, with (i) one quarter of the shares vesting on March 11, 2022, (ii) one quarter of the shares vesting on March 11, 2023, (iii) one quarter of the shares vesting on March 11, 2024, and (iv) one quarter of the shares vesting on March 11, 2025. F5 · derivative.expiration_date: This restricted stock unit award was granted on March 11, 2021 with respect to 9,000 Common Shares, with (i) one quarter of the shares vesting on March 11, 2022, (ii) one quarter of the shares vesting on March 11, 2023, (iii) one quarter of the shares vesting on March 11, 2024, and (iv) one quarter of the shares vesting on March 11, 2025. Read SEC document |
| March 11, 2021 Filed Mar 12, 2021 22:43 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | GrantStock Option (Right to Buy) · Derivative | 25,360 | $0.00 Strike: $133.88 | $0.00 |
DisclosureSEC source: 0001209191-21-020253 · doc4.xml · derivative · entry 3 KASINGER JAMES R. · CIK 0001708172 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,360 Underlying: Common Shares · 25,360 shares Expires 2031-03-11 F4 · derivative.exercise_date: This option was granted on March 11, 2021 with respect to 25,360 Common Shares. 100% of the shares will vest in 48 equal monthly installments, with the first vesting date of April 11, 2021. Read SEC document |
| March 10, 2021 Filed Mar 12, 2021 22:43 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Tax withholdingCommon Shares | 1,353 | $124.15 | $167,974.95 |
DisclosureSEC source: 0001209191-21-020253 · doc4.xml · nonDerivative · entry 2 KASINGER JAMES R. · CIK 0001708172 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,911 F3 · shares: Amount reported represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of these restricted stock units. This sale is mandated by the Company's RSU Settlement Policy to fund the tax withholding obligation and does not represent a discretionary trade by the reporting person. Read SEC document |
| March 10, 2021 Filed Mar 12, 2021 22:43 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionCommon Shares | 2,833 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-020253 · doc4.xml · nonDerivative · entry 1 KASINGER JAMES R. · CIK 0001708172 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,264 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: This restricted stock unit award was granted on March 10, 2020 with respect to 8,500 Common Shares, with (i) one third of the shares vesting on March 10, 2021, (ii) one third of the shares vesting on March 10, 2022, and (iii) one third of the shares vesting on March 10, 2023. F2 · price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. Read SEC document |
| January 19, 2021 Filed Jan 20, 2021 23:05 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionStock Option (right to buy) · Derivative | 27,500 | $0.00 Strike: $51.49 | $0.00 |
DisclosureSEC source: 0001209191-21-004452 · doc4.xml · derivative · entry 7 KASINGER JAMES R. · CIK 0001708172 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Shares · 27,500 shares Expires 2028-03-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: This option was granted on March 7, 2018 with respect to 40,000 Common Shares and vests in 48 equal monthly installments. Read SEC document |
| January 19, 2021 Filed Jan 20, 2021 23:05 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | SaleCommon Shares | 2,100 | $207.61 | $435,981.00 |
DisclosureSEC source: 0001209191-21-004452 · doc4.xml · nonDerivative · entry 6 KASINGER JAMES R. · CIK 0001708172 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,431 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $207.39 to $208.1050, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| January 19, 2021 Filed Jan 20, 2021 23:05 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | SaleCommon Shares | 1,800 | $206.05 | $370,890.00 |
DisclosureSEC source: 0001209191-21-004452 · doc4.xml · nonDerivative · entry 5 KASINGER JAMES R. · CIK 0001708172 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,531 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $206.00 to $206.51, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.